MCL1 as a therapeutic vulnerability in Burkitt lymphoma

Leukemia. 2023 Apr;37(4):934-937. doi: 10.1038/s41375-023-01827-x. Epub 2023 Feb 2.

Authors

Ren Yuan^#¹, Michelle Y Wang^#², Chengfeng Bi³, Xiaohong Zhao¹, Jianguo Tao⁴

Affiliations

¹ Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 33612, USA.
² Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
³ Department of Pathology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
⁴ Department of Pathology, University of Virginia Medical Center, Charlottesville, VA, 22903, USA. wrw6qu@virginia.edu.

^# Contributed equally.

PMID: 36732564
DOI: 10.1038/s41375-023-01827-x

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Burkitt Lymphoma* / drug therapy
Burkitt Lymphoma* / genetics
Burkitt Lymphoma* / pathology
Humans
Myeloid Cell Leukemia Sequence 1 Protein / genetics

Substances

MCL1 protein, human
Myeloid Cell Leukemia Sequence 1 Protein